Navigation Links
'Drug-Free' Stent Coating Shows Promise
Date:1/21/2008

Trial finds polymer reduces inflammatory reaction associated with current devices

MONDAY, Jan. 21 (HealthDay News) -- A new kind of coated stent holds promise for overcoming the major problems with these tubes that are inserted to keep arteries open after clot-clearing angioplasty, Italian researchers report.

The new stent is not coated with drugs, like the latest generation in medical use, but with a special polymer designed to prevent thrombosis and restenosis, formation of new clots and buildup of deposits that re-clog the blood vessels, Dr. Corrado Tamburino told the International Symposium of Endovascular Therapy meeting on Monday in Hollywood, Fla.

A trial in which the new stents were inserted in 55 people who underwent angioplasty showed excellent results, said Tamburino, professor of cardiology at the University of Catania, where the procedures were performed.

"We had no thrombosis, no deaths, no myocardial infarctions [heart attacks] at six months," Tamburino said.

In addition, close examination of the arteries showed re-growth of fatty deposits only in the smallest vessels, Tamburino said. "In large vessels, restenosis was nil," he said.

The results were especially remarkable, because one-third of the stent recipients were diabetic and thus more vulnerable to problems, and all participants got only 30 days of the clot-preventing drug Plavix, he said. Current U.S. recommendations are for six months to a year of Plavix after stent implantation.

The polymer used to coat the stent was developed by CeloNova Biosciences, a Georgia-based biotechnology company. It is designed "to reduce inflammation and immune responses to the stent," Tamburino said.

"A polymer coating with almost no inflammatory action is an interesting concept," said Dr. Ramon Quesada, director of interventional cardiology at the Baptist Cardiac and Vascular Institute of Miami, after he heard Tamburino's report. "There is potentially lower chance of thrombosis."

But it's much too early to start drawing definitive conclusions about the new stents, Quesada said. "These are very preliminary data," he said. "We cannot make too much of it because the numbers in the trial are very small. This is an interesting observation, and we have to see the results of more trials."

Future trials would have to match results of angioplasty using existing drug-coated stents with the new polymer-coated stents, Tamburino said. Such trials would take years to produce definitive information, he said.

More information

You can learn more about stents from the American Heart Association.



SOURCES: Corrado Tamburino, M.D., Ph.D., professor of cardiology, University of Catania, Italy; Ramon Quesada, M.D., director of interventional cardiology, Baptist Cardiac and Vascular Institute of Miami; Jan. 21, 2008, meeting, International Symposium of Endovascular Therapy, Hollywood, Fla.


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Drug-free treatments offer hope for older people in pain
2. MetLife Foundation Begins New Phase of Award-Winning Parenting Skills Campaign in Collaboration with the Partnership for a Drug-Free America(R)
3. Partnership for a Drug-Free America and Colorado Springs Police Department Introduce Methamphetamine Prevention Program to Colorado Law Enforcement
4. Partnership for a Drug-Free America and Council Bluffs Police Department Introduce Methamphetamine Prevention Program to Iowa Law Enforcement
5. Supernanny Jo Frost Joins the Partnership for a Drug-Free America in Supporting Time To Talk(TM)
6. U.S. Secretary of Labor launches Drug-Free Work Week
7. AssistNow Offers Area Employers Complimentary Needs Assessment in Recognition of National Drug-Free Work Week
8. Statement of Steve Pasierb, President and CEO, Partnership for a Drug-Free America on the Release of the 2007 Monitoring the Future Study
9. Dr. Drew Joins the Partnership for a Drug-Free America in Supporting TimeToTalk(TM)
10. Statement of Steve Pasierb, President and CEO, Partnership for a Drug-Free America on New SAMHSA Study On Cough Medicine Abuse
11. Investigators uncover intriguing clues to why persistent acid reflux sometimes turns into cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
'Drug-Free' Stent Coating Shows Promise
(Date:4/25/2017)... Richmond, BC (PRWEB) , ... April 25, 2017 , ... ... patients from Richmond, BC, who live with dental fear and require sedation to receive ... anxiety at ease during various procedures, from hygienic cleanings to oral surgery, at ...
(Date:4/25/2017)... , ... April 25, 2017 , ... ... they rely on contracted partners to help with process innovation in drug formulation ... drug formulation experience along with state-of-the-art analytical equipment in support of their development ...
(Date:4/25/2017)... MN (PRWEB) , ... April 25, 2017 , ... Buyers ... and recreational users to dispensaries and head shops –can’t help but be heartened by ... for the tell-tale cannabis odor aptly described as “skunk smell.” At last they ...
(Date:4/25/2017)... ... 25, 2017 , ... Emergency Physician and Distinguished Professor of Emergency Medicine Bentley ... in Writing, set to publish in summer 2017. , Dr. Bobrow, MD, FACEP, ... Arizona College of Medicine. He also serves as Medical Director for the Bureau of ...
(Date:4/25/2017)... ... April 25, 2017 , ... Amendia, Inc., designer, developer, and ... partnership with and platinum sponsorship of Global Spine Outreach (“GSO”), a charitable organization ... of complex spine deformity cases, particularly in children. , GSO’s focus is to ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... April 19, 2017 Global Surgical Drainage Device ... tubes used to remove excess liquid and air. The ... urine, bile or lymph. Surgical drains are used in ... as orthopedics surgery, cardiovascular surgery, neurosurgery, plastic surgery etc. ... to prevent accumulation of fluid e.g. blood or pus. ...
(Date:4/19/2017)... 19, 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... company developing new treatments for cancer and other ... its previously announced underwritten public offering of 23,625,084 ... offering price of $2.00 per share, before deducting ... payable by Sorrento.  The net proceeds to Sorrento ...
(Date:4/19/2017)... , April 19, 2017  SARES•REGIS Group ... it is developing at Conejo Spectrum Business Park ... to Atara Biotherapeutics, Inc. , a biopharmaceutical ... and life-threatening diseases that have been underserved by ... T-cell therapies for cancer, autoimmune and infectious disease. ...
Breaking Medicine Technology: